Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Sickle Cell Disease
NCT00639392Phase 2Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Jun 2007
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Zoledronic Acid with Placebo (2 arms). Primary endpoint: Prevention or reduction of pain at 1 year. Planned start Jun 2007; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00639392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00639392.